BACKGROUND: Epithelioid sarcoma (ES) and unclassified sarcoma with epithelioid features (USEF) are clinically and therapeutically unresolved. We compared ES and USEF patients' clinical behavior, treatment, outcome, and molecular marker expression. Furthermore, preclinical ES study models were developed to enable comprehensive benchside investigations. PATIENTS AND METHODS: A database of ES and USEF patients (n = 116) treated since 1992 was created. A clinically annotated ES-USEF tissue microarray (TMA) was assayed for tumor-related markers. Newly established human and commercially available ES cell lines were characterized and tested in vivo. RESULTS: ES and USEF patients presenting with localized disease exhibited 22% and 25% local recurrence rates, 35% and 19% nodal metastasis rates, and 41% and 53% distant metastasis rates (median follow-up, 54 months and 39 months, respectively). The 5- and 10-year disease-specific survival rates were 88% and 43% and 52% and 42% (ES and USEF, respectively). TMA immunohistochemistry identified integrase interactor (INI)-1 loss, cancer antigen 125, and p53 nuclear expression as significantly more common in ES than USEF cases. Both cell lines preserved ES morphological and biochemical characteristics in vitro and in vivo; loss of INI-1 was shown to occur in both lines. CONCLUSIONS: Enhanced knowledge of ES and USEF clinical behavior, marker expression, and molecular determinants, extended via experimental models, will hopefully accelerate development of urgently needed effective targeted therapies for ES and USEF.
BACKGROUND:Epithelioid sarcoma (ES) and unclassified sarcoma with epithelioid features (USEF) are clinically and therapeutically unresolved. We compared ES and USEF patients' clinical behavior, treatment, outcome, and molecular marker expression. Furthermore, preclinical ES study models were developed to enable comprehensive benchside investigations. PATIENTS AND METHODS: A database of ES and USEF patients (n = 116) treated since 1992 was created. A clinically annotated ES-USEF tissue microarray (TMA) was assayed for tumor-related markers. Newly established human and commercially available ES cell lines were characterized and tested in vivo. RESULTS: ES and USEF patients presenting with localized disease exhibited 22% and 25% local recurrence rates, 35% and 19% nodal metastasis rates, and 41% and 53% distant metastasis rates (median follow-up, 54 months and 39 months, respectively). The 5- and 10-year disease-specific survival rates were 88% and 43% and 52% and 42% (ES and USEF, respectively). TMA immunohistochemistry identified integrase interactor (INI)-1 loss, cancer antigen 125, and p53 nuclear expression as significantly more common in ES than USEF cases. Both cell lines preserved ES morphological and biochemical characteristics in vitro and in vivo; loss of INI-1 was shown to occur in both lines. CONCLUSIONS: Enhanced knowledge of ES and USEF clinical behavior, marker expression, and molecular determinants, extended via experimental models, will hopefully accelerate development of urgently needed effective targeted therapies for ES and USEF.
Authors: Jue Liu; Maocheng Zhan; Jonathan A F Hannay; Parimal Das; Svetlana V Bolshakov; Dhanashankren Kotilingam; Dihua Yu; Alexander F Lazar; Raphael E Pollock; Dina Lev Journal: Mol Cancer Res Date: 2006-10-31 Impact factor: 5.852
Authors: Laila Chbani; Louis Guillou; Philippe Terrier; Anne Valérie Decouvelaere; Fleur Grégoire; Marie José Terrier-Lacombe; Dominique Ranchère; Yves Marie Robin; Françoise Collin; Paul Fréneaux; Jean-Michel Coindre Journal: Am J Clin Pathol Date: 2009-02 Impact factor: 2.493
Authors: Guy Lahat; Quan-Sheng Zhu; Kai-Lieh Huang; Suizhao Wang; Svetlana Bolshakov; Jeffery Liu; Keila Torres; Robert R Langley; Alexander J Lazar; Mien Chie Hung; Dina Lev Journal: PLoS One Date: 2010-04-16 Impact factor: 3.240
Authors: Changye Zou; Kerrington D Smith; Jun Liu; Guy Lahat; Sarah Myers; Wei-Lien Wang; Wei Zhang; Ian E McCutcheon; John M Slopis; Alexander J Lazar; Raphael E Pollock; Dina Lev Journal: Ann Surg Date: 2009-06 Impact factor: 12.969
Authors: Markus Weisskopf; Ralph Münker; Benita Hermanns-Sachweh; Jörg A K Ohnsorge; Christian Siebert Journal: Eur Spine J Date: 2006-02-11 Impact factor: 3.134
Authors: Elizabeth G Demicco; Paul W Harms; Rajiv M Patel; Steven C Smith; Davis Ingram; Keila Torres; Shannon L Carskadon; Sandra Camelo-Piragua; Jonathan B McHugh; Javed Siddiqui; Nallasivam Palanisamy; David R Lucas; Alexander J Lazar; Wei-Lien Wang Journal: Am J Clin Pathol Date: 2015-05 Impact factor: 2.493
Authors: Gonzalo Lopez; Yechun Song; Ryan Lam; Dennis Ruder; Chad J Creighton; Hemant Kumar Bid; Kate Lynn Bill; Svetlana Bolshakov; Xiaoli Zhang; Dina Lev; Raphael E Pollock Journal: Mol Cancer Res Date: 2015-09-22 Impact factor: 5.852
Authors: Xianbiao Xie; Markus P H Ghadimi; Eric D Young; Roman Belousov; Quan-Sheng Zhu; Juehui Liu; Gonzalo Lopez; Chiara Colombo; Tingsheng Peng; David Reynoso; Jason L Hornick; Alexander J Lazar; Dina Lev Journal: Clin Cancer Res Date: 2011-08-05 Impact factor: 12.531
Authors: Samuel V Rasmussen; Jia Xiang Jin; Lissett R Bickford; Andrew D Woods; Felix Sahm; Kenneth A Crawford; Kiyo Nagamori; Hiroaki Goto; Keila E Torres; Angelo Sidoni; Erin R Rudzinski; Khin Thway; Robin L Jones; Alessio Ciulli; Hollis Wright; Melvin Lathara; Ganapati Srinivasa; Kavya Kannan; Paul H Huang; Thomas G P Grünewald; Noah E Berlow; Charles Keller Journal: Clin Transl Med Date: 2022-07
Authors: Jonathan Noujaim; Khin Thway; Zia Bajwa; Ayeza Bajwa; Robert G Maki; Robin L Jones; Charles Keller Journal: Front Oncol Date: 2015-08-17 Impact factor: 6.244
Authors: Mohamed Réda El Ochi; Mohammed Massine El Hammoumi; Abdelhamid Biyi; Mohamed Allaoui; El Hassane Kabiri; Abderrahman Albouzidi; Mohamed Oukabli Journal: J Med Case Rep Date: 2016-10-03
Authors: Anneke Alves; Anastasia Constantinidou; Khin Thway; Cyril Fisher; Paul Huang; Robin L Jones Journal: Eur J Cancer Care (Engl) Date: 2021-07-18 Impact factor: 2.328